Rxreliance

C-PEPTIDE (HUMAN). 0.5mg The measurement of the C-peptide under standardized conditions provides a sensitive, well accepted, and clinically validated assessment of +-cell function. The C-peptide measurement is the most suitable primary outcome for clinical trials of therapies aimed at preserving or improving endogenous insulin secretion in type 1 diabetes patients.eC-peptide also shows hormonal activity. Clinical studies demonstrated that C-peptide administration in type 1 diabetes patients, who lack the peptide, alleviates the diabetes-induced renal and nerve dysfunctions. CAS: 33017-11-7 C129H211N35O48 FW: 3020.3 . Synonym: Insulin Precursor (57-87) (human)

C-PEPTIDE (HUMAN). 1mg The measurement of the C-peptide under standardized conditions provides a sensitive, well accepted, and clinically validated assessment of +-cell function. The C-peptide measurement is the most suitable primary outcome for clinical trials of therapies aimed at preserving or improving endogenous insulin secretion in type 1 diabetes patients.eC-peptide also shows hormonal activity. Clinical studies demonstrated that C-peptide administration in type 1 diabetes patients, who lack the peptide, alleviates the diabetes-induced renal and nerve dysfunctions. CAS: 33017-11-7 C129H211N35O48 FW: 3020.3 . Synonym: Insulin Precursor (57-87) (human)

(DES-HIS1,GLU9)-GLUCAGON (1-29) AMI, 0.5mg Glucagon antagonist. CAS: 110084-95-2 C148H221N41O47S FW: 3358.7. glucagon.

(DES-HIS1,GLU9)-GLUCAGON (1-29) AMI, 1mg Glucagon antagonist. CAS: 110084-95-2 C148H221N41O47S FW: 3358.7. glucagon.

MINIGLUCAGON (HUMAN, RAT, PORCINE), 5mg This glucagon fragment inhibited both the Ca2activated and mg 2+ dependent ATPase activity and Ca2+ transport in liver plasma membranes with an efficiency 1000-fold higher than that of glucagon. It is likely to be the active peptide involved in the inhibition of the liver Ca2+ pump..

EXENDIN-4 (3-39). 0.5mg Potent glucagon-like peptide 1 (GLP-1) receptor antagonist. CAS: 196109-31-6 C176H272N46O58S FW: 3992.44 . exendin

EXENDIN-4 (3-39). 1mg Potent glucagon-like peptide 1 (GLP-1) receptor antagonist. CAS: 196109-31-6 C176H272N46O58S FW: 3992.44 . exendin

(SER8)-GLP-1 (7-36) AMIDE (HUMAN, BOVINE, GUINEA PIG, MOUSE, RAT) 0.5mg The replacement of alanine by serine significantly improved the plasma stability of GLP-1 (7-36) amide against DPP IV without impairing its insulinotropic activity. This may indicate that this modification could improve the potential of GLP-1 in the treatment of type-II diabetes. CAS: 215777-46-1 C149H226N40O46 FW: 3313.68. Synonym: (Ser8)-Glucagon-Like Peptide 1 (7-36) amide (human, bovine, guinea pig, mouse, rat), (Ser79)-Proglucagon (78-107) amide (human, bovine, guinea pig, mouse, rat), (Ser99)-Preproglucagon (98-127) amide (human, bovine, guinea pig, mouse, rat).

(SER8)-GLP-1 (7-36) AMIDE (HUMAN, BOVINE, GUINEA PIG, MOUSE, RAT) 1mg The replacement of alanine by serine significantly improved the plasma stability of GLP-1 (7-36) amide against DPP IV without impairing its insulinotropic activity. This may indicate that this modification could improve the potential of GLP-1 in the treatment of type-II diabetes. CAS: 215777-46-1 C149H226N40O46 FW: 3313.68. Synonym: (Ser8)-Glucagon-Like Peptide 1 (7-36) amide (human, bovine, guinea pig, mouse, rat), (Ser79)-Proglucagon (78-107) amide (human, bovine, guinea pig, mouse, rat), (Ser99)-Preproglucagon (98-127) amide (human, bovine, guinea pig, mouse, rat).

GLP-2 (1-34) (HUMAN). 0.5mg CAS: 99120-49-7 C171H266N48O56S FW: 3922.35 . Synonym: Glucagon-Like Peptide 2-Arg (human), Preproglucagon (146-179) (human), Proglucagon (126-159) (human)

GLP-2 (1-34) (HUMAN). 1mg CAS: 99120-49-7 C171H266N48O56S FW: 3922.35 . Synonym: Glucagon-Like Peptide 2-Arg (human), Preproglucagon (146-179) (human), Proglucagon (126-159) (human)

GLP-2 (RAT). 0.5mg GLP-2 administration to mice or rats promotes stimulation of crypt cell proliferation and inhibition of enterocyte apoptosis resulting in hyperplasia of the small bowel villous epithelium. It also exerts trophic effects in animal models of both small and large bowel injury such as experimental small bowel resection or chemically induced colitis. In addition to stimulation of epithelial proliferation, GLP-2 also acutely regulates gastric emptying and exerts rapid metabolic effects promoting stimulation of intestinal hexose transport. The actions of GLP-2 are transduced via the GLP-2 receptor, a member of the glucagon-secretin G protein-coupled receptor superfamily. CAS: 195262-56-7 C166H256N44O56S FW: 3796.19 . Synonym: Glucagon-Like Peptide 2 (rat), Preproglucagon (14....

GLP-2 (RAT). 1mg GLP-2 administration to mice or rats promotes stimulation of crypt cell proliferation and inhibition of enterocyte apoptosis resulting in hyperplasia of the small bowel villous epithelium. It also exerts trophic effects in animal models of both small and large bowel injury such as experimental small bowel resection or chemically induced colitis. In addition to stimulation of epithelial proliferation, GLP-2 also acutely regulates gastric emptying and exerts rapid metabolic effects promoting stimulation of intestinal hexose transport. The actions of GLP-2 are transduced via the GLP-2 receptor, a member of the glucagon-secretin G protein-coupled receptor superfamily. CAS: 195262-56-7 C166H256N44O56S FW: 3796.19 . Synonym: Glucagon-Like Peptide 2 (rat), Preproglucagon (146....

GLP-1 (1-37) (HUMAN, BOVINE, GUINEA PIG) 0.5mg Glucagon-Like Peptide 1 (GLP-1) is synthesized by posttranslational processing of proglucagon in the intestine and pancreas and plays an important role in metabolic homeostasis. Among the different molecular forms, such as GLP-1 (7-36) amide and GLP-1 (7-37), the function of GLP-1 (1-37) has been unclear. GLP-1 (1-37) was shown to convert intestinal epithelial cells into insulin-producing cells. These observations turned GLP-1 (1-37) into a new promising therapeutic compound for the treatment of diabetes mellitus. In animal models of dilated cardiomyopathy, hypertensive heart failure, and myocardial infarction, GLP-1 has shown a remarkable cardioprotective activity. CAS: 87805-34-3 C186H275N51O59 FW: 4169.54. Synonym: Glucagon-Like Peptide 1 (.....

GLP-1 (1-37) (HUMAN, BOVINE, GUINEA PIG) 1mg Glucagon-Like Peptide 1 (GLP-1) is synthesized by posttranslational processing of proglucagon in the intestine and pancreas and plays an important role in metabolic homeostasis. Among the different molecular forms, such as GLP-1 (7-36) amide and GLP-1 (7-37), the function of GLP-1 (1-37) has been unclear. GLP-1 (1-37) was shown to convert intestinal epithelial cells into insulin-producing cells. These observations turned GLP-1 (1-37) into a new promising therapeutic compound for the treatment of diabetes mellitus. In animal models of dilated cardiomyopathy, hypertensive heart failure, and myocardial infarction, GLP-1 has shown a remarkable cardioprotective activity. CAS: 87805-34-3 C186H275N51O59 FW: 4169.54. Synonym: Glucagon-Like Peptide 1 (1-.....

GIP (HUMAN). 0.5mg Gastric inhibitory polypeptide (GIP), an incretin, represents an essential regulator of insulin secretion and glucose homeostasis. CAS: 100040-31-1 C226H338N60O66S FW: 4983.6 . Synonym: GIP (human), Glucose-Dependent Insulinotropic Polypeptide (human)

GIP (HUMAN). 1mg Gastric inhibitory polypeptide (GIP), an incretin, represents an essential regulator of insulin secretion and glucose homeostasis. CAS: 100040-31-1 C226H338N60O66S FW: 4983.6 . Synonym: GIP (human), Glucose-Dependent Insulinotropic Polypeptide (human)

GLP-2 (1-33) (HUMAN). 0.5mg Like GLP-1, GLP-2 is secreted from enteroendocrine cells in a nutrient-dependent manner in both rodents and humans. Currently GLP-2 is used as a potential therapeutic agent for human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency. CAS: 223460-79-5 C165H254N44O55S FW: 3766.16 . Synonym: Glucagon-Like Peptide 2 (human), Preproglucagon (146-178) (human), Proglucagon (126-158) (human)

GLP-2 (1-33) (HUMAN). 1mg Like GLP-1, GLP-2 is secreted from enteroendocrine cells in a nutrient-dependent manner in both rodents and humans. Currently GLP-2 is used as a potential therapeutic agent for human subjects with a broad variety of intestinal diseases characterized by intestinal damage and insufficiency. CAS: 223460-79-5 C165H254N44O55S FW: 3766.16 . Synonym: Glucagon-Like Peptide 2 (human), Preproglucagon (146-178) (human), Proglucagon (126-158) (human)

BIOTINYL-GLUCAGON (1-29) (HUMAN. 0.5mg C163H239N45O51S2 FW: 3709.1 . glucagon

GLP-1 (7-36) AMIDE (CHICKEN, COMMON TURKEY) 0.5mg C149H224N40O47 FW: 3327.66. Synonym: Glucagon-Like Peptide 1 (7-36) amide (chicken, common turkey), Preproglucagon (118-147) amide (chicken, common turkey), Proglucagon (96-125) amide (chicken, common turkey).

GLP-1 (7-36)-LYS(6-FAM) AMIDE (HU. 0.5mg C176H248N42O52 FW: 3784.16 . Synonym: Glucagon-Like Peptide 1 (7-36)-Lys(6-FAM) amide (human, bovine, guinea pig, mouse, rat), Preproglucagon (98-127)-Lys(6-FAM)amide (human, bovine, guinea pig, mouse, rat), Proglucagon (78-107)-Lys(6-FAM) amide (human, bovine, guinea pig, mouse, rat)

GLP-1 (7-36)-LYS(6-FAM) AMIDE (HU. 1mg C176H248N42O52 FW: 3784.16 . Synonym: Glucagon-Like Peptide 1 (7-36)-Lys(6-FAM) amide (human, bovine, guinea pig, mouse, rat), Preproglucagon (98-127)-Lys(6-FAM)amide (human, bovine, guinea pig, mouse, rat), Proglucagon (78-107)-Lys(6-FAM) amide (human, bovine, guinea pig, mouse, rat)

GLP-1 (7-36)-LYS(BIOTINYL) AMIDE . 0.5mg C165H252N44O48S FW: 3652.15 . Synonym: Glucagon-Like Peptide 1 (7-36)-Lys(biotinyl) amide (human, bovine, guinea pig, mouse, rat), Preproglucagon (98-127)-Lys(biotinyl) amide (human, bovine, guinea pig, mouse, rat), Proglucagon (78-107)-Lys(biotinyl) amide (human, bovine, guinea pig, mouse, rat)

GLP-1 (1-36) AMIDE (HUMAN, BOVINE) 0.5mg CAS: 99658-04-5 C184H273N51O57 FW: 4111.5. Synonym: Glucagon-Like Peptide 1 (1-36) amide (human, bovine, guinea pig, mouse, rat), Preproglucagon (92-127) amide (human, bovine, guinea pig, mouse, rat), Proglucagon (72-107) amide (human, bovine, guinea pig, mouse, rat).

GLP-1 (1-36) AMIDE (HUMAN, BOVINE) 1mg CAS: 99658-04-5 C184H273N51O57 FW: 4111.5. Synonym: Glucagon-Like Peptide 1 (1-36) amide (human, bovine, guinea pig, mouse, rat), Preproglucagon (92-127) amide (human, bovine, guinea pig, mouse, rat), Proglucagon (72-107) amide (human, bovine, guinea pig, mouse, rat).

GRPP (HUMAN). 0.5mg GRPP (human) also known as glicentin-related polypeptide (human) is a synthetic analog of a cleavage product resulting from proglucagon processing in pancreatic +- and intestinal L-cells. CAS: 1132745-52-8 C136H215N41O58S FW: 3384.51 . Synonym: Glicentin-Related Polypeptide (human), Preproglucagon (21-50) (human), Proglucagon (1-30) (human)

GRPP (HUMAN). 1mg GRPP (human) also known as glicentin-related polypeptide (human) is a synthetic analog of a cleavage product resulting from proglucagon processing in pancreatic +- and intestinal L-cells. CAS: 1132745-52-8 C136H215N41O58S FW: 3384.51 . Synonym: Glicentin-Related Polypeptide (human), Preproglucagon (21-50) (human), Proglucagon (1-30) (human)

(MET(O)27)-GLUCAGON (1-29) (HUMAN. 0.5mg This glucagon derivative shows the same maximal glucose mobilizing activity in rat hepatocytes as native glucagon, but it is less potent, sug gesting a crucial role of methionine in the binding of glucagon to its hepatic receptor. CAS: 75217-63-9 C153H225N43O50S FW: 3498.8 . glucagon

(MET(O)27)-GLUCAGON (1-29) (HUMAN. 1mg This glucagon derivative shows the same maximal glucose mobilizing activity in rat hepatocytes as native glucagon, but it is less potent, sug gesting a crucial role of methionine in the binding of glucagon to its hepatic receptor. CAS: 75217-63-9 C153H225N43O50S FW: 3498.8 . glucagon

(DES-THR5)-GLUCAGON. 0.5mg C149H218N42O47S FW: 3381.69 . glucagon

(DES-THR5)-GLUCAGON. 1mg C149H218N42O47S FW: 3381.69 . glucagon

(DES-THR7)-GLUCAGON. 0.5mg C149H218N42O47S FW: 3381.69 . glucagon

(DES-THR7)-GLUCAGON. 1mg C149H218N42O47S FW: 3381.69 . glucagon

GLP-1 (7-36) AMIDE (HUMAN, BOVINE) 0.5mg This GLP-1 fragment is secreted from the lower small intestine and shows a strong insulinotropic effect. GLP-1 (7-36) amide is considered as the most important incretin hormone. Its action is mediated by receptors expressed by the endocrine pancreatic B-cells. Considerable interest has focused on the development of this peptide as a therapeutic strategy for non-insulin-dependent (type 2 ) diabetes mellitus and associated neuropathy. CAS: 107444-51-9 C149H226N40O45 FW: 3297.68. Synonym: Glucagon-Like Peptide 1 (7-36) amide (human, bovine, guinea pig, mouse, rat), Preproglucagon (98-127) amide (human, bovine, guinea pig, mouse, rat), Proglucagon (78-107) amide (human, bovine, guinea pig, mouse, rat).

GLP-1 (7-36) AMIDE (HUMAN, BOVINE) 1mg This GLP-1 fragment is secreted from the lower small intestine and shows a strong insulinotropic effect. GLP-1 (7-36) amide is considered as the most important incretin hormone. Its action is mediated by receptors expressed by the endocrine pancreatic B-cells. Considerable interest has focused on the development of this peptide as a therapeutic strategy for non-insulin-dependent (type 2 ) diabetes mellitus and associated neuropathy. CAS: 107444-51-9 C149H226N40O45 FW: 3297.68. Synonym: Glucagon-Like Peptide 1 (7-36) amide (human, bovine, guinea pig, mouse, rat), Preproglucagon (98-127) amide (human, bovine, guinea pig, mouse, rat), Proglucagon (78-107) amide (human, bovine, guinea pig, mouse, rat).

EXENATIDE. 0.5mg Exendin-4 (exenatide), originally isolated from Heloderma suspectum venom, differs from exendin-3 by only 2 N-terminal amino acid substitutions. This polypeptide causes an increase in acinar cAMP without stimulating amylase release. Exendin-4 and glucagon-like peptide 1 (7-36) amide bind with similar affinity to the glucagon-like peptide 1 receptor. Moreover, exendin-4 is also considered for clinical use in the treatment of type 2 diabetes. CAS: 141758-74-9 C184H282N50O60S FW: 4186.63 . Synonym: Exendin-4

EXENATIDE. 1mg Exendin-4 (exenatide), originally isolated from Heloderma suspectum venom, differs from exendin-3 by only 2 N-terminal amino acid substitutions. This polypeptide causes an increase in acinar cAMP without stimulating amylase release. Exendin-4 and glucagon-like peptide 1 (7-36) amide bind with similar affinity to the glucagon-like peptide 1 receptor. Moreover, exendin-4 is also considered for clinical use in the treatment of type 2 diabetes. CAS: 141758-74-9 C184H282N50O60S FW: 4186.63 . Synonym: Exendin-4

EXENDIN-3. 0.5mg Exendin-3, a member of the glucagon superfamily, was originally isolated from the venom of the lizard, Heloderma horridum. At low concentrations, the 39-amino acid peptide interacts with putative exendin receptors causing an increase in pancreatic acinar cAMP, whereas at higher concentrations it interacts with VIP receptors to stimulate an increase in cellular cAMP and amylase release. CAS: 130357-25-4 C184H282N50O61S FW: 4202.63 . exendin

EXENDIN (9-39). 0.5mg Exendin (9-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. It has also been described as an antagonist of the putative exendin receptor. This peptide blocks the stimulatory action of GLP-1 (7- 36) amide (H- 6795) and of exendin-4 (H- 8730) on cAMP production in pancreatic acini. - Moreover, exendin (9-39) was shown to be safely used to abolish the incretin effect of GLP-1 without interfering with the control of insulin secretion by circulating nutrients. CAS: 133514-43-9 C149H234N40O47S FW: 3369.8 . exendin

EXENDIN (9-39). 1mg Exendin (9-39) is a potent glucagon-like peptide 1 (GLP-1) receptor antagonist. It has also been described as an antagonist of the putative exendin receptor. This peptide blocks the stimulatory action of GLP-1 (7- 36) amide (H- 6795) and of exendin-4 (H- 8730) on cAMP production in pancreatic acini. - Moreover, exendin (9-39) was shown to be safely used to abolish the incretin effect of GLP-1 without interfering with the control of insulin secretion by circulating nutrients. CAS: 133514-43-9 C149H234N40O47S FW: 3369.8 . exendin

GLP-1 (7-37) (HUMAN, BOVINE, GUINEA PIG) 0.5mg An insulinotropic peptide generated by proteolytic cleavage of its precursor GLP-1 (1-37) and secreted by L cells of the intestinal mucosa upon food ingestion. CAS: 106612-94-6 C151H228N40O47 FW: 3355.71. Synonym: Glucagon-Like Peptide 1 (7-37) (human, bovine, guinea pig, mouse, rat), Insulinotropin (human, bovine, guinea pig, mouse, rat), Proglucagon (78-108) (human, bovine, guinea pig, mouse, rat), Preproglucagon (98-128) (human, bovine, guinea pig, mouse, rat).

GLP-1 (7-37) (HUMAN, BOVINE, GUINEA PIG) 1mg An insulinotropic peptide generated by proteolytic cleavage of its precursor GLP-1 (1-37) and secreted by L cells of the intestinal mucosa upon food ingestion. CAS: 106612-94-6 C151H228N40O47 FW: 3355.71. Synonym: Glucagon-Like Peptide 1 (7-37) (human, bovine, guinea pig, mouse, rat), Insulinotropin (human, bovine, guinea pig, mouse, rat), Proglucagon (78-108) (human, bovine, guinea pig, mouse, rat), Preproglucagon (98-128) (human, bovine, guinea pig, mouse, rat).

H-Glu(EDANS)-Lys-Pro-Ala-Lys-Phe-Phe-Arg-Leu-Lys(DABCYL)-NH2.